Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:investor
|
| gptkbp:country |
gptkb:Switzerland
|
| gptkbp:focusesOn |
gptkb:medical_device
gptkb:biotechnology life sciences |
| gptkbp:foundedBy |
gptkb:Novartis
|
| gptkbp:foundedYear |
1996
|
| gptkbp:headquartersLocation |
Basel
|
| gptkbp:industry |
venture capital
|
| gptkbp:investedIn |
startups
private companies early stage growth stage |
| gptkbp:parentOrganization |
gptkb:Novartis
|
| gptkbp:portfolioCompany |
gptkb:CytomX_Therapeutics
gptkb:Adimab gptkb:Molecular_Partners gptkb:Heptares_Therapeutics gptkb:Nexthink Celyad F2G Nabriva Therapeutics Polyphor Vaximm |
| gptkbp:website |
https://www.nvfund.com/
|
| gptkbp:bfsParent |
gptkb:Faze_Medicines
gptkb:Flare_Therapeutics |
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Novartis Venture Fund
|